Actively Recruiting
Study of Gemtesa and Placebo to Evaluate Blood Vessel Function in Aging Women Using Beta3 Adrenergic Receptors
Led by University of Missouri-Columbia · Updated on 2026-09-10
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether vascular beta3 adrenergic receptors exist and function in aging women, aiming to see if targeting these receptors can reduce sympathetic vasoconstriction and improve vascular function during aging and menopause. This early phase 1 trial focuses on healthy women between 18 and 70 years old. The study is sponsored by the University of Missouri-Columbia and uses a randomized, single-masked, crossover design to explore these basic science questions. Participants will receive oral gemtesa 75 mg or a placebo pill in a crossover format. They will undergo two experimental tests a cold pressor test involving ice water applied to the foot to stimulate vascular response, and a flow-mediated dilation test using high-resolution ultrasound following cuff inflation on the forearm. These interventions and tests aim to assess vascular function and blood flow changes. During the study, participants will be monitored for changes in blood flow from baseline to 2 minutes after intervention. Researchers will evaluate vascular responses using ultrasound and blood pressure measurements. The trial involves multiple visits for testing and monitoring, with a study duration extending to May 2029. Safety and adherence will be tracked throughout, including exclusion of participants with certain health conditions or risks.
CONDITIONS
Brief Title
Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women
Research Team
J
Jacqueline Limberg Associate Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here